Therapeutic advances in acute ischaemic stroke

International Journal of Clinical Practice

Volumn 53, Issue 4, 1999, Pages 295-300

  Bhalla, A ^a   Rudd, A G ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; STREPTOKINASE;

BLOOD CLOT LYSIS; CELL DAMAGE; CEREBROVASCULAR ACCIDENT; HUMAN; NEUROPROTECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECANALIZATION; REPERFUSION INJURY; REVIEW;

EID: 0033066392     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Bamford J, Sandercock P, Dennis M et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project, 1981-86. J Neurol Neurosurg Psychiatry 1990; 53: 16-22.
2. Hossmann KA. Viability thresholds and penumbra of focal ischaemia. Ann Neurol 1994; 36: 557-565.
3. Baron JC, Von Kummer R, Del Zoppo. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke 1995; 26: 2219-2221.
4. Fisher M. Characterizing the target of acute stroke therapy. Stroke 1997; 28: 866-872.
5. Pulsinelli W. Pathophysiology of acute ischaemic stroke. Lancet 1992; 339: 533-536.
6. McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br J Clin Pharmacol 1992; 34: 106-114.
7. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343: 831-836.
8. Winquist RJ, Kerr S. Cerebral ischemia-reperfusion injury and adhesion: advances in stroke management. Neurology 1997; 49(4): S23-S26.
9. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-1649.
10. International Stroke Trial (IST) Investigators. Randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.
11. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42.
12. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
13. Counsell C, Sandercock P. Anticoagulant therapy compared to control in patients with acute presumed ischaemic stroke (Cochrane Review). In: The Cochrane Library, 1998, Issue 2. Oxford: Update Software.
14. Counsell C, Sandercock P. The use of low molecular weight heparins or heparinoids compared to standard unfractionated heparin in acute ischaemic stroke (Cochrane Review). In: The Cochrane Library, 1998, Issue 2. Oxford: Update Software.
15. The Publications Committee for the Trial of ORG 10172 in Acute Stoke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid) and outcome after acute ischemic stroke: a randomised controlled trial. JAMA 1998; 279: 1265-1272.
16. Hacke W. Thrombolytic therapy in acute ischemic stroke: an update. Fibrinolysis 1994; 8: 216-220.
17. Von Kummer R, Meyding-Lamade U, Forsting M et al. sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. Am J Neuroradiol 1994; 15: 9-15.
18. Forsting M, Krieger D, Von Kummer R et al. The prognostic value of collateral blood flow in acute middle cerebral artery occlusion. In: del Zoppo GJ, Mori E, Hacke W, Eds. Thrombolytic therapy in acute ischaemic stroke II. New York: Springer Verlag 1993: 160-167.
19. Sussman BJ, Fitch TSP. Thrombolysis with fibrinolysis in cerebral arterial occlusion. JAMA 1958; 167: 1705-1709.
20. FTT Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardiat infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
21. Multicentre Acute Stroke Trial - Italy (MAST-I). Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509-1514.
22. Multicentre Acute Stroke Trial - Europe (MAST-E). Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145-150.
23. Donnan GA, Davis SM, Chambers BR et al, for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of admission. JAMA 1996; 276: 961-966.
24. Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemisphere stroke: European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
25. Hacke W, Kaste M, Fiesschi C et al. Randomised double blind placebocontrolled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASSII) Lancet 1998; 352: 1245-1251.
26. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute stroke. N Engl J Med 1995; 333: 1581-1587.
27. Adams HP Jr, Brott TG, Furlan AJ et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Stroke 1996; 27: 1711-1718.
28. del Zoppo GJ, Higashida RT, Furlan AJ et al, for the PROACT Investigators. The prolyse in acute cerebral thromboembolism trial (PROACT): results of 6 mg dose tier. Stroke 1996; 27: 164.
29. Wardlaw JM, Warlow CP, Counsell C. Systemic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997; 350: 607-614.
30. Wardlaw JM, Yamaguchi T, del Zoppo G. Thrombolytic therapy versus control in acute ischaemic stroke. In: The Cochrane Library, 1998, Issue 4. Oxford: Update Software.
31. Singer MB, Chong J, Lu D. Diffusion weighted MRI in acute subcortical infarction. Stroke 1998; 29: 133-136.
32. Mosley M, de Crespigny A, Tong T et al. Clinical MR diffusion/perfusion protocol for hyperacute stroke. Vancouver: International Society for Magnetic Resonance in Medicine, 1997.
33. Fisher M, Prichard JW, Warach S. New magnetic resonance techniques for acute ischemic stroke. JAMA 1995; 274: 908-911.
34. Felber SR, Archner FT, Sauter R et al. Combined magnetic resonance imaging aand proton magnetic resonance spectroscopy of patients with acute stroke. Stroke 1992; 23: 1106-1110.
35. Pancioli A, Broderick J, Kothari R et al. Public perception of stroke warning signs and potential risk factors. Stroke 1997; 28: 236.
36. Lyden PD, Rapp K, Babcock JP et al. Ultra rapid identification, triage and enrolment of stroke patients into clinical trials. J Stroke Cerebrovasc Dis 1994; 4: 106-113.
37. Mori E, Takakura K, Yamaguchi T et al. Multicenter trial of a novel modified t-PA, E6010 by i.v bolus injection in patients with acute carotid artery territory stroke. Cerebrovasc Dis 1996; 6: 191.
38. Thomas DJ, du Boulay GH, Marshall J et al. Prevention of stroke: the viscosity factor. In Meyer JS, Lechner H, Reivich M, Eds. Cerebral vascular disease 2. 9th Salzburg Conference 1978: 211.
39. Bell WR. Defibrinogenating enzymes. Drugs 1997; 54(suppl 3): 18-31.
40. Ancrod Stroke Study Investigators. Ancrod for treatment of ischemic brain infarction. Stroke 1994; 25: 1755-1759.
41. Mohr JP, Orgogozo JM, Harrison MJG et al. Meta-analysis of oral nimodopine trials in acute ischemic stroke. Cerebrovasc Dis 1994; 4: 197-203.
42. Norris JW, LeBrun LH, Andersen BA (Canwin Study Stroke Group). Intravenous nimodipine in acute ischemic stroke. Cerebrovasc Dis 1994; 4: 194-196.
43. Wahlgren NG, MacMahon DG, DeKeyser J et al, for the INWEST study group. Intravenous Nimodopine West European Stroke Trial (INWEST) of nimodopine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994: 4: 204-210.
44. Limburg M, Horn J, Vermeulen M, for the VENUS group. Very early nimodopine use in stroke (VENUS). Stroke 1996; 27: 361.
45. Grotta J, Clark W, Coull B et al. Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischémie stroke: results of a phase IIa randomised trial. Stroke 1995; 26: 602-605.
46. Edwards K, and the CNS 1102-008 study group. Cerestat (Aptiganel) in the treatment of acute ischemic stroke: results of a phase II trial. Neurology 1996; 46: A424 (abstract).
47. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995; 26: 503-513.
48. Kulagowski JJ, Leeson PD. Glycine site NMDA receptor antagonists. Exp Opin Ther Patients 1995; 5: 1061-1075.
49. Smith SE, Leekieffre D, Sowinski P et al. Cerebroprotective effect of BW619C89 after focal or global cerebral ischemia in the rat. Neuroreport 1993; 4: 1339-1342.
50. Lesage AS, Peeters L, Leyson JF. Lubeluzole, a novel long term neuroprotectant, inhibits the glutamate activated nitric oxide synthase pathway. J Pharmacol Exp Ther 1996; 279: 759-766.
51. Grotta J, for the US and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment of acute ischemic stroke. Stroke 1997: 28: 2338-2346.
52. Diener H. Multinational randomised controlled trial of lubeluzole in acute ischemic stroke. Cerebrovasc Dis 1998; 8: 172-181.
53. Valenzuaela GJ, Munson LA. Magnesium and pregnancy. Magnesium 1987; 6(3): 128-135.
54. Muir KW, Lees KR. A randomised, double blind controlled pilot trial of intravenous magnesium sulphate in acute stroke. Stroke 1995; 26: 1183-1188.
55. Koh J, Goldberg MP, Hartley DM et al. Non NMDA receptor mediated neurotoxicity in cortical culture. J Neurosci 1990; 10: 693-705.
56. Nellgard B, Wieloch T. Post ischemic blockade of AMPA but not NMDA receptors mitigates neuronal damage in the rat brain following transient severe cerebral ischemia. J Cereb Blood Flow Metab 1992; 12: 2-11.
57. Silver B, Weber J, Fisher M. Medical therapy for acute ischemic stroke. Clin Neuropharmacol 1995; 19: 101-128.
58. Turski L, Huth A, Sheardown M et al. ZK200775: a phosponale quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci USA 1998; 95(18): 10960-10965.
59. Morika E, Moskowitz MA, Huang Z et al. Arginine infusion promotes nitric oxide dependant vasodilatation, increases regional cerebral blood flow and reduces infarction volume in the rat. Stroke 1994; 25: 429-435.
60. Yoshida T, Limmroth V, Irikura K et al. The NOS inhibitor 7-nitroindazole decreases focal infarct volume but not the response to acetylcholine in pial vessels. J Cereb Blood Flow Metab 1994; 14: 924-929.
61. Zheng GZ, Reif D, Macdonald J et al. ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1996; 16: 599-604.
62. Fisher M, Meadows ME, Do T et al. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1995; 15: 953-959.
63. Kawamata T, Alexia NE, Dietrich WD et al. Intracisternal basic fibroblast growth factor enhances behavioural recovery following cerebral infarction in the rat. J Cereb Blood Flow Metab 1996; 16: 542-547.
64. Wahlgren NG, and the Clomethiazole Acute Stroke Study Collaborative Group. The Clomethiazole Acute Stroke Study (CLASS). Cerebrovasc Dis 1997; 7(suppl 4): 19.
65. De Deyn PP, De Reuck J, Deberdt W et al. Piracetam in Acute Stroke (PASS). Eur J Neurol 1995; 2: 7.
66. Clark WM, Williams BJ, Selzer KA et al. Randomised efficacy trial of citicoline in acute ischemic stroke. Stroke 1998; 29: 287 (abstract).
67. Nowak TS Jr, Ikeda J, Nakajima T. 70 kDA heat shock protein and c fos gene expression after transient ischemia. Stroke 1990; 21(suppl III): 107-111.
68. Fassbender K, Mossner R, Motsch L et al. Circulating selectin and immunoglobulin type adhesion molecules in acute ischemic stroke. Stroke 1995: 26: 1361-1364.
69. Fassbender K, Rossol S, Kammer T et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci 1994; 122: 135-139.
70. Bowes MP, Zivin JA, Rothlein R. Monoclonal antibody to ICAM 1 adhesion site reduces neurological damage in a rabbit cerebral stroke model. Exp Neurol 1993; 119: 215-219.
71. Enlimomab Acute Stroke Trial investigators. The Enlimomab Acute Stroke Trial: final results. Neurology 1997; 48: A270 (abstract).
72. RANTASS Investigators. A randomised trial of tirilizad mesylate in patients with acute ischemic stroke. Stroke 1996; 27: 1453-1458.
73. European Ad Hoc Consensus Group. Neuroprotectants initial therapy in acute stroke. Cerebrovasc Dis 1998; 8: 59-72.
74. European Ad Hoc Consensus Group. Optimising intensive care in stroke: a European perspective. Cerebrovasc Dis 1997; 7: 113-128.
75. Powers W. Acute hypertension after stroke: the scientific basis for treatment decisions. Neurology 1993; 43: 461-467.
76. O'Connell JE, Gray CS. Treating hypertension after stroke. BMJ 1994; 308: 1523-1524.
77. Blood Pressure in Acute Stroke Collaboration (BASC). Blood pressure management in acute stroke. Part I: Assessment of trials designed to alter blood pressure (Cochrane Review). In: The Cochrane Library, Issue 2, 1998. Oxford: Update Software.
78. Kannell WB, McGee DL. Diabetes and cerebrovascular disease: the Framingham study. JAMA 1979; 241: 2035-2038.
79. Jorgensen HS, Nakayama H, Raaschou H et al. Stroke in patients with diabetes: the Copenhagen study. Stroke 1994; 25: 1977-1984.
80. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after stroke? Results of a long term follow-up. BMJ 1997; 314: 1303-1306.
81. Ryden M, Efendic S et al. Randomised trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
82. Reith J, Jorgsensen S, Pedersen P et al. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet 1996; 347: 422-425.
83. Chyatte D, Elefteriades J, Kim B. Profound hypothermia and circulatory arrest for aneurysm surgery. J Neurosurg 1989; 70: 489-491.